[1]袁满,金玮,郝昕蕾,等.糖尿病视网膜病变神经血管损伤发病机制的研究进展[J].眼科新进展,2020,40(9):885-888.[doi:10.13389/j.cnki.rao.2020.0201]
　YUAN Man,JIN Wei,HAO Xinlei,et al.Research advances in the pathogenesis of neurovascular injury in diabetic retinopathy[J].Recent Advances in Ophthalmology,2020,40(9):885-888.[doi:10.13389/j.cnki.rao.2020.0201]
点击复制

糖尿病视网膜病变神经血管损伤发病机制的研究进展/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
40卷
期数:
2020年9期
页码:
885-888
栏目:
文献综述
出版日期:
2020-09-05

文章信息/Info

Title:
Research advances in the pathogenesis of neurovascular injury in diabetic retinopathy
作者:
袁满; 金玮; 郝昕蕾; 杨安怀
430060　湖北省武汉市，武汉大学人民医院眼科中心
Author(s):
YUAN Man; JIN Wei; HAO Xinlei; YANG Anhuai
The Eye Center of People’s Hospital of Wuhan University,Wuhan 430060,Hubei Province,China
关键词:
糖尿病视网膜病变; 神经血管单元; 发病机制; 微血管损伤; 神经损伤
Keywords:
diabetic retinopathy;  neurovascular unit;  pathogenesis;  microvascular impairment;  neurodegeneration
分类号:
R774
DOI:
10.13389/j.cnki.rao.2020.0201
文献标志码:
A
摘要:
糖尿病视网膜病变(diabetic retinopathy,DR)曾被认为是糖尿病微血管病变的并发症，如今已被广泛认为是神经血管单元（neurovascular unit,NVU）损伤引起的一类神经血管性疾病。研究表明，在出现临床可检测的微血管病变之前，视网膜神经损伤已经出现，并参与了微血管病变的进展。因此，微血管病变这一观点并没有揭示视网膜神经元、神经胶质细胞和血管间相互联系及影响的重要性。以NVU作为整体研究神经血管损伤及保护机制，寻找临床新的预防和干预DR的措施必定成为未来研究的热点。
Abstract:
Diabetic retinopathy (DR) was earlier recognized as a microvascular complication, but nowadays, it is considered as a neurovascular disorder caused by damage to neurovascular units. Study shows that changes in the neuronal damage occurs before the clinically detectable microvascular abnormalities shortly after diabetes and neuronal damage participates in the progress of microvascular disease. Therefore, microangiopathy does not reveal the importance of the connections and impact between the neurons, glial cells and microvessels. Furthermore, the neurovascular damage and its protective mechanism based on the neurovascular unit and the novel therapeutic measures for DR will be the focuses of research in future.

参考文献/References:

［1］DAS A.Diabetic retinopathy:a global epidemic ［J］.Middle East Afr J Ophthalmol,2015,22(2):133-134.
［2］　HENRIQUES J,VAZ-PEREIRA S,NASCIMENTO J,ROSA P C.Diabetic eye disease［J］.Acta Med Port,2015,28(1):107-113.
［3］　KIRSCH S,IROKU-MALIZE T.Eye conditions in older adults:Diabetic Retinopathy ［J］.FP Essent,2016,445：29-37.
［4］　DAS A.Diabetic retinopathy:Battling the global epidemic［J］.Indian J Ophthalmol,2016,64(1):2-3.
［5］　SIMO R,STITT A W,GARDNER T W.Neurodegeneration in diabetic retinopathy:does it really matter?［J］.Diabetologia,2018,61(9):1902-1912.
［6］　JONSSON K B,FRYDKJAER-OLSEN U,GRAUSLUND J.Vascular changes and neurodegeneration in the early stages of diabetic retinopathy:which comes first?［J］.Ophthalmic Res,2016,56(1):1-9.
［7］　BARBER A J,BACCOUCHE B.Neurodegeneration in diabetic retinopathy:Potential for novel therapies ［J］.Vision Res,2017,139：82-92.
［8］　GARDNER T W,DAVILA J R.The neurovascular unit and the pathophysiologic basis of diabetic retinopathy ［J］.Graefes Arch Clin Exp Ophthalmol,2017,255(1):1-6.
［9］　DUH E J,SUN J K,STITT A W.Diabetic retinopathy:current understanding,mechanisms,and treatment strategies ［J］.JCI Insight,2017,2(14):e93751.
［10］　PETZOLD G C,MURTHY V N.Role of astrocytes in neurovascular coupling ［J］.Neuron,2011,71(5):782-797.
［11］　FILOSA J A,MORRISON H W,IDDINGS J A,DU W,KIM K J.Beyond neurovascular coupling,role of astrocytes in the regulation of vascular tone ［J］.Neuroscience,2016,323：96-109.
［12］　SCHAFER D P,LEHRMAN E K,KAUTZMAN A G,KOYAMA R,MARDINLY A R,YAMASAKI R,et al.Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner ［J］.Neuron,2012,74(4):691-705.
［13］　NEWMAN E A.Functional hyperemia and mechanisms of neurovascular coupling in the retinal vasculature ［J］.J Cereb Blood Flow Metab,2013,33(11):1685-1695.
［14］　METEA M R,NEWMAN E A.Signalling within the neurovascular unit in the mammalian retina ［J］.Exp Physiol,2007,92(4):635-640.
［15］　MUOIO V,PERSSON P B,SENDESKI M M.The neurovascular unit - concept review ［J］.Acta Physiol (Oxf),2014,210(4):790-798.
［16］　IADECOLA C.The Neurovascular unit coming of age:a journey through neurovascular coupling in health and disease ［J］.Neuron,2017,96(1):17-42.
［17］　FEHER J,TAURONE S,SPOLETINI M,BIRO Z,VARSANYI B,SCUDERI G,et al.Ultrastructure of neurovascular changes in human diabetic retinopathy ［J］.Int J Immunopathol Pharmacol,2017,31:1-7.
［18］　JACKSON G R,SCOTT I U,QUILLEN D A,WALTER L E,GARDNER T W.Inner retinal visual dysfunction is a sensitive marker of non-proliferative diabetic retinopathy ［J］.Br J Ophthalmol,2012,96(5):699-703.
［19］　GUALTIERI M,BANDEIRA M,HAMER R D,DAMICO F M,MOURA A L,VENTURA D F.Contrast sensitivity mediated by inferred magno- and parvocellular pathways in type 2 diabetics with and without nonproliferative retinopathy ［J］.Invest Ophthalmol Vis Sci,2011,52(2):1151-1155.
［20］　PARDUE M T,BARNES C S,KIM M K,AUNG M H,AMARNATH R,OLSON D E,et al.Rodent hyperglycemia-induced inner retinal deficits are mirrored in human diabetes ［J］.Transl Vis Sci Technol,2014,3(3):6.
［21］　HARRISON W W,BEARSE M A,J R,NG J S,JEWELL N P,BAREZ S,BURGER D,et al.Multifocal electroretinograms predict onset of diabetic retinopathy in adult patients with diabetes ［J］.Invest Ophthalmol Vis Sci,2011,52(2):772-777.
［22］　LOTT M E,SLOCOMB J E,SHIVKUMAR V,SMITH B,GABBAY R A,QUILLEN D,et al.Comparison of retinal vasodilator and constrictor responses in type 2 diabetes ［J］.Acta Ophthalmol,2012,90(6):e434-e441.
［23］　LIM L S,LING L H,ONG P G,FOULDS W,TAI E S,WONG T Y.Dynamic responses in retinal vessel caliber with flicker light stimulation and risk of diabetic retinopathy and its progression ［J］.Invest Ophthalmol Vis Sci,2017,58(5):2449-2455.
［24］　LASTA M,PEMP B,SCHMIDL D,BOLTZ A,KAYA S,PALKOVITS S,et al.Neurovascular dysfunction precedes neural dysfunction in the retina of patients with type 1 diabetes ［J］.Invest Ophthalmol Vis Sci,2013,54(1):842-847.
［25］　ARASZKIEWICZ A,ZOZULINSKA-ZIOLKIEWICZ D.Retinal Neurodegeneration in the course of diabetes-pathogenesis and clinical perspective ［J］.Curr Neuropharmacol,2016,14(8):805-809.
［26］　KADLUBOWSKA J,MALAGUARNERA L,WAZ P,ZORENA K.Neurodegeneration and neuroinflammation in diabetic retinopathy:potential approaches to delay neuronal loss ［J］.Curr Neuropharmacol,2016,14(8):831-839.
［27］　BEHL T,KOTWANI A.Downregulated brain-derived neurotrophic factor-induced oxidative stress in the pathophysiology of diabetic retinopathy［J］.Can J Diabetes,2017,41(2):241-246.
［28］　BOSS J D,SINGH P K,PANDYA H K,TOSI J,KIM C,TEWARI A,et al.Assessment of neurotrophins and inflammatory mediators in vitreous of patients with diabetic retinopathy ［J］.Invest Ophthalmol Vis Sci,2017,58(12):5594-5603.
［29］　ALTMANN C,SCHMIDT M H H.The role of microglia in diabetic retinopathy:inflammation,microvasculature defects and neurodegeneration ［J］.Int J Mol Sci,2018,19(1):110.
［30］　CUENCA N,FERNANDEZ-SANCHEZ L,CAMPELLO L,MANEU V,DE LA VILLA P,LAX P,et al.Cellular responses following retinal injuries and therapeutic approaches for neurodegenerative diseases ［J］.Prog Retin Eye Res,2014,43:17-75.
［31］　SUBIRADA P V,PAZ M C,RIDANO M E,LORENC V E,VAGLIENTI M V,BARCELONA P F,et al.A journey into the retina:Müller glia commanding survival and death ［J］.Eur J Neurosci,2018,47(12):1429-1443.
［32］　CHUNG S S,CHUNG S K.Aldose reductase in diabetic microvascular complications ［J］.Curr Drug Targets,2005,6(4):475-486.
［33］　HOTTA N,KAWAMORI R,FUKUDA M,SHIGETA Y,ALDOSE REDUCTASE INHIBITOR-DIABETES COMPLICATIONS TRIAL STUDY G.Long-term clinical effects of epalrestat,an aldose reductase inhibitor,on progression of diabetic neuropathy and other microvascular complications:multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy ［J］.Diabet Med,2012,29(12):1529-1533.
［34］　KADOR P F,WYMAN M,OATES P J.Aldose reductase,ocular diabetic complications and the development of topical Kinostat((R)) ［J］.Prog Retin Eye Res,2016,54:1-29.
［35］　WU M Y,YIANG G T,LAI T T,LI C J.The oxidative stress and mitochondrial dysfunction during the pathogenesis of diabetic retinopathy ［J］.Oxid Med Cell Longev,2018,2018:3420187.
［36］　BEHL T,KAUR I,KOTWANI A.Implication of oxidative stress in progression of diabetic retinopathy ［J］.Surv Ophthalmol,2016,61(2):187-196.
［37］　GERALDES P,KING G L.Activation of protein kinase C isoforms and its impact on diabetic complications ［J］.Circ Res,2010,106(8):1319-1331.
［38］　PATHAK D,GUPTA A,KAMBLE B,KUPPUSAMY G,SURESH B.Oral targeting of protein kinase C receptor:promising route for diabetic retinopathy?［J］.Curr Drug Deliv,2012,9(4):405-413.
［39］　KHANGHOLI S,MAJID F A,BERWARY N J,AHMAD F,AZIZ R B.The mechanisms of inhibition of advanced glycation end products formation through polyphenols in hyperglycemic condition ［J］.Planta Med,2016,82(1-2):32-45.
［40］　XU J,CHEN L J,YU J,WANG H J,ZHANG F,LIU Q,et al.Involvement of advanced glycation end products in the pathogenesis of diabetic retinopathy ［J］.Cell Physiol Biochem,2018,48(2):705-717.
［41］　LAU J C,KROES R A,MOSKAL J R,LINSENMEIER R A.Diabetes changes expression of genes related to glutamate neurotransmission and transport in the Long-Evans rat retina ［J］.Mol Vis,2013,19:1538-1553.
［42］　LI Q,PURO D G.Diabetes-induced dysfunction of the glutamate transporter in retinal Müller cells ［J］.Invest Ophthalmol Vis Sci,2002,43(9):3109-3116.
［43］　AHSAN H.Diabetic retinopathy--biomolecules and multiple pathophysiology ［J］.Diabetes Metab Syndr,2015,9(1):51-54.
［44］　CERVIA D,CASINI G,BAGNOLI P.Physiology and pathology of somatostatin in the mammalian retina:a current view ［J］.Mol Cell Endocrinol,2008,286(1-2):112-122.
［45］　SIMO R,HERNANDEZ C,PORTA M,BANDELLO F,GRAUSLUND J,HARDING S P,et al.Effects of topically administered neuroprotective drugs in early stages of diabetic retinopathy:results of the EUROCONDOR clinical trial ［J］.Diabetes,2019,68(2):457-463.
［46］　SORRENTINO F S,ALLKABES M,SALSINI G,BONIFAZZI C,PERRI P.The importance of glial cells in the homeostasis of the retinal microenvironment and their pivotal role in the course of diabetic retinopathy ［J］.Life Sci,2016,162:54-59.
［47］　GRIGSBY J G,CARDONA S M,POUW C E,MUNIZ A,MENDIOLA A S,TSIN A T,et al.The role of microglia in diabetic retinopathy ［J］.J Ophthalmol,2014,2014:705-783.
［48］　GRAEBER M B,LI W,RODRIGUEZ M L.Role of microglia in CNS inflammation ［J］.FEBS Lett,2011,585(23):3798-805.
［49］　HOLM T H,DRAEBY D,OWENS T.Microglia are required for astroglial Toll-like receptor 4 response and for optimal TLR2 and TLR3 response ［J］.Glia,2012,60(4):630-638.
［50］　ZENG H Y,GREEN W R,TSO M O.Microglial activation in human diabetic retinopathy ［J］.Arch Ophthalmol,2008,126(2):227-232.
［51］　NAGAI N,IZUMI-NAGAI K,OIKE Y,KOTO T,SATOFUKA S,OZAWA Y,et al.Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway ［J］.Invest Ophthalmol Vis Sci,2007,48(9):4342-4350.
［52］　COUGHLIN B A,FEENSTRA D J,MOHR S.Muller cells and diabetic retinopathy ［J］.Vision Res,2017,139:93-100.
［53］　STAHEL M,BECKER M,GRAF N,MICHELS S.Systemic interleukin 1beta inhibition in proliferative diabetic retinopathy:A Prospective Open-Label Study Using Canakinumab ［J］.Retina,2016,36(2):385-391.
［54］　CHERNYKH V V,VARVARINSKY E V,SMIRNOV E V,CHERNYKH D V,TRUNOV A N.Proliferative and inflammatory factors in the vitreous of patients with proliferative diabetic retinopathy ［J］.Indian J Ophthalmol,2015,63(1):33-36.
［55］　LIU Y,TAO L,FU X,ZHAO Y,XU X.BDNF protects retinal neurons from hyperglycemia through the TrkB/ERK/MAPK pathway ［J］.Mol Med Rep,2013,7(6):1773-1778.
［56］　HAMMES H P,FEDEROFF H J,BROWNLEE M.Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes ［J］.Mol Med,1995,1(5):527-534.
［57］　MYSONA B A,SHANAB A Y,ELSHAER S L,EL-REMESSY A B.Nerve growth factor in diabetic retinopathy:beyond neurons ［J］.Expert Rev Ophthalmol,2014,9(2):99-107.
［58］　ZANG J,GUAN G.Study of pigment epithelium-derived factor in pathogenesis of diabetic retinopathy ［J］.Eye Sci,2015,30(2):81-88.
［59］　YOSHIDA Y,YAMAGISHI S,MATSUI T,JINNOUCHI Y,FUKAMI K,IMAIZUMI T,et al.Protective role of pigment epithelium-derived factor (PEDF) in early phase of experimental diabetic retinopathy ［J］.Diabetes Metab Res Rev,2009,25(7):678-686.

相似文献/References:

[1]杜玮 刘子扬 周艳艳 雒雷鸣.糖尿病视网膜病变与血清胆红素水平的关系[J].眼科新进展,2012,32(5):000.
[2]范松涛 卢建民.阿司匹林与糖尿病患者玻璃体出血以及玻璃体切割术疗效的相关性研究[J].眼科新进展,2012,32(11):000.
[3]李艳 李筱荣 袁佳琴 潘斌.糖尿病大鼠视网膜中VEGF、PEDF的表达与血-视网膜屏障损伤[J].眼科新进展,2013,33(1):000.
[4]李朝晖 崔治华 胡晓英 孟丽珠 张敬维.糖尿病视网膜病变激光面积与疗效的分析[J].眼科新进展,2013,33(2):000.
[5]冯冬梅 朱鸿 施彩虹.CXC趋化因子及其受体在糖尿病视网膜病变中的作用[J].眼科新进展,2013,33(6):000.
[6]牛淑玲.糖尿病视网膜病变患者HbAlc、FPG与血小板参数的变化及危险因素分析[J].眼科新进展,2013,33(7):000.
[7]毕春潮 王睿 王建洲 雷春灵 董晓娟 王小莉 薛晓辉.Ad-PEDF对糖尿病视网膜病变大鼠视网膜新生血管的抑制作用[J].眼科新进展,2013,33(8):000.
[8]杨萍 孙书明 李晓鹏.辛伐他汀对糖尿病视网膜病变和炎症因子的影响[J].眼科新进展,2013,33(8):000.
[9]罗文婷 孙大卫.血管黏附蛋白-1在眼科疾病中的研究进展[J].眼科新进展,2013,33(8):000.
[10]李小璐 马雅玲.糖尿病视网膜病变大鼠视网膜VEGF和PEDF的动态表达[J].眼科新进展,2013,33(9):000.
[11]朱君雅,姚文,倪锡森,等.糖尿病性黄斑水肿的病理生理机制：神经血管单元研究现状[J].眼科新进展,2023,43(1):066.[doi:10.13389/j.cnki.rao.2023.0014]
　ZHU Junya,YAO Wen,NI Xinsen,et al.Pathophysiology of diabetic macular edema: current status of neurovascular unit research[J].Recent Advances in Ophthalmology,2023,43(9):066.[doi:10.13389/j.cnki.rao.2023.0014]

备注/Memo

备注/Memo:
N/A
更新日期/Last Update: 2020-09-05